Finance

Beta
Ask
Lists
IMRN:NASDAQ
Immuron Ltd - ADR
$1.06
-0.93%
(-0.010) 1D
Jun 18, 4:00:00 PM GMT-4  ·   USD
All symbols
SymbolPriceChange% Change
Generating top insights for IMRN...
Open
$1.07
High
$1.07
Low
$1.04
Mkt. cap
7.55M
Avg. vol.
463.33K
Volume
8.59K
52-wk high
$2.38
52-wk low
$0.68
EPS
-$0.52
Beta
1.12
Shares outstanding
8.17M
No. of employees
7
Open
$1.07
High
$1.07
Low
$1.04
Mkt. cap
7.55M
Avg. vol.
463.33K
Volume
8.59K
52-wk high
$2.38
52-wk low
$0.68
EPS
-$0.52
Beta
1.12
Shares outstanding
8.17M
No. of employees
7
News stories
From sources across the web
Profile
Immuron is a biotechnology company based in Melbourne, Australia. In 2008, the company changed its name to Immuron Limited, having previously operated as Anadis Limited. Immuron is focused on antigen-primed and dairy-derived health products. Its proprietary technologies allow for rapid development of polyclonal antibody and other proteins-based solutions for a range of diseases. The company specialises in nutraceutical, pharmaceutical and therapeutic technology products for conditions such as oral and GI mucositis, avian influenza, E. coli travellers' diarrhoea and Anthrax containment. In 2005, Anadis signed an agreement with Quebec's Baralex Inc. and Valeo Pharma Inc. for the distribution of Travelan, a product made by Anadis for the Canadian market. Wikipedia
About Immuron Ltd - ADR
CEO-
Employees7
Founded1994
HeadquartersBlackburn North, Victoria, Australia
SectorBiotechnology
Websiteimmuron.com.au
Previous reportsAll values in AUD
Loading Previous Earnings...
Income statement
Revenue
Net income
All values in AUD
Mar 2025
Jun 2025
Sep 2025
Dec 2025
Revenue
1.65M
1.65M
2.09M
2.09M
Cost of goods sold
592.31K
592.31K
765.33K
765.33K
Cost of revenue
592.31K
592.31K
765.33K
765.33K
Research and development expenses
807.58K
807.58K
589.74K
589.74K
Total research and development expenses
-
-
-
-
Selling, general, and admin expenses
2.04M
2.04M
1.89M
1.89M
Operating expense
2.46M
2.46M
2.31M
2.31M
Total operating expenses
3.06M
3.06M
3.08M
3.08M
Operating income
-1.41M
-1.41M
-986.57K
-986.57K
Other non operating income
-
-
-
-
EBT including unusual items
-1.36M
-1.36M
-959.54K
-959.54K
EBT excluding unusual items
-1.36M
-1.36M
-959.54K
-959.54K
Income tax expense
-
-
-
-
Effective tax rate
-
-
-
-
Other operating expenses
-382.63K
-382.63K
-167.08K
-167.08K
Net income
-1.36M
-1.36M
-959.54K
-959.54K
Net profit margin
-82.83%
-82.83%
-45.86%
-45.86%
Earnings per share
-
-
-
-
Interest and investment income
40.94K
40.94K
30.32K
30.32K
Interest expense
-1.64K
-1.64K
-3.29K
-3.29K
Net interest expenses
39.30K
39.30K
27.03K
27.03K
Depreciation and amortization charges
-
-
-
-
EBITDA
-1.40M
-1.40M
-974.15K
-974.15K
Gain or loss from assets sale
-
-
-
-
Insider transactions
Insider transactions data is drawn from third-party sources. Learn more
Insider
Position
Type
Date
Shares
Amount
Page 1
AI content may include mistakes. Learn more
HelpSend feedbackPrivacyTermsDisclaimer
AI content may include mistakes. Learn more
HelpSend feedbackPrivacyTermsDisclaimer